STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Active, not recruiting
- Lymphoma, Mantle Cell
- Mantle Cell Lymphoma
- Rituximab (R)
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2021-09-21
Sep 21, 2021E
Active, not recruiting
- Multiple Myeloma
- Bortezomib
- Dexamethasone
- Rionero in Vulture, Potenza, ItalyIrccs Crob
2022-03-24
Mar 24, 2022C
Recruiting
- Relapsed or Refractory Multiple Myeloma
- Mitoxantrone Hydrochloride Liposome injection
- +2 more
- Beijing, Beijing, ChinaBeijing Chaoyang Hospital, Capital Medical University
2022-01-16
Jan 16, 2022S
Recruiting
- Antibody-mediated Rejection
- Bortezomib
- Tehran, Iran, Islamic Republic ofSBMU
2022-01-27
Jan 27, 2022H
Recruiting
- Hematological Malignancy
- Bortezomib
- Detroit, MichiganHenry Ford hospital
2021-12-23
Dec 23, 2021P
Not yet recruiting
- Thrombotic Thrombocytopenic Purpura, Acquired
- Bortezomib Injection
- Beijing, (Select), ChinaPeking Union Medical College Hospital
2021-11-22
Nov 22, 2021P
Recruiting
- Diffuse Large B Cell Lymphoma
- Ibrutinib and Bortezomib + R-CHOP
- Berlin, GermanyCharité - Universitätsmedizin Berlin, Hematology, Oncology and T
2022-02-19
Feb 19, 2022H
Recruiting
- Glioblastoma
- Bortezomib and Temozolomide Phase IB
- Bortezomib and Temozolomide Phase II
- Bergen, Norway
- +1 more
2021-08-24
Aug 24, 2021N
Recruiting
- Neoplasms
- +2 more
- Bortezomib plus Clofarabine
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022M
Active, not recruiting
- Solid Tumor
- Urethral Cancer
- Bortezomib
- +2 more
- Houston, TexasUniversity of Texas MD Anderson Cancer Center
2022-02-21
Feb 21, 2022P
Recruiting
- Autoimmune Hemolytic Anemia
- Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
- combination of a single dose anti-CD20 antibody and bortezomib
- Beijing, Beijing, ChinaPeking Union Medical College Hospital
2021-10-12
Oct 12, 2021U
Completed
- Multiple Myeloma
- Vorinostat Velcade Dexamethasone
- Nottingham, Nottinghamshire, United Kingdom
- +1 more
2021-08-09
Aug 9, 2021N
Recruiting
- Graft-versus-host Disease
- Cyclophosphamide
- +2 more
- New York, New YorkNYU Langone Health
2022-03-24
Mar 24, 2022U
Completed
- Hodgkin's Lymphoma
- Lymphoma, Non-Hodgkin
- Bortezomib
- Ruxolitinib
- Ann Arbor, MichiganUniversity of Michgan Comprehensive Cancer Center
2021-12-03
Dec 3, 2021H
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +2 more
- Bortezomib
- Mexico City, MexicoHospital General de México "Dr. Eduardo Liceaga"
2022-01-02
Jan 2, 2022C
N
Completed
- Lung Diseases, Interstitial
- +2 more
- Bortezomib
- +2 more
- Chicago, IllinoisNorthwestern University
2021-08-02
Aug 2, 2021M
E
Completed
- Multiple Myeloma
- Bortezomib
- +3 more
- Atlanta, GeorgiaEmory University Winship Cancer Institute
2021-11-01
Nov 1, 2021R
Terminated
- Follicular Lymphoma
- Bortezomib and Tositumomab I-131
- Chicago, IllinoisRush University Medical Center
2021-10-06
Oct 6, 2021M
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +2 more
- Rochester, MinnesotaMayo Clinic in Rochester
2021-10-06
Oct 6, 2021N
Completed
- Chronic Myeloid Leukemia (CML)
- +4 more
- Bortezomib
- NK cells
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022M
P
Recruiting
- Multiple Myeloma
- Myeloma
- Isatuximab
- +3 more
- Poitiers, FranceCHU Poitiers
2021-11-03
Nov 3, 2021U
Active, not recruiting
- Waldenström's Macroglobulinemia
- Dexamethasone, Rituximab, Cyclophosphamide
- Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
- Ulm, GermanyUniversity Hospital Ulm
2021-05-03
May 3, 2021